NeuroSense Therapeutics Ltd. (NRSN) Free cash flow 2021–2025
NeuroSense Therapeutics Ltd. (NRSN) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$7.7MFY2025 · since FY2021: -$1.6M → -$7.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$7.7M | +24.3% |
| FY2024 | -$10.1M | -20.9% |
| FY2023 | -$8.4M | -9.1% |
| FY2022 | -$7.7M | -394.0% |
| FY2021 | -$1.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More NRSN financial trends
NRSN RevenueNRSN Net incomeNRSN Net marginNRSN Gross profitNRSN Gross marginNRSN Operating incomeNRSN Operating marginNRSN Operating cash flowNRSN Capital expendituresNRSN Return on equityNRSN Stock buybacksNRSN Dividends paidNRSN Total assetsNRSN Total liabilitiesNRSN Shareholders’ equityNRSN overview →